Quick Answer
Cellectar Biosciences, Inc. reported Net Income of -$21.79 million for fiscal year 2025.
Cellectar Biosciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$21.79M +51.1% |
-$44.58M -4.2% |
-$42.77M -49.5% |
-$28.60M -18.6% |
-$24.12M -59.8% |
-$15.09M -7.1% |
| Diluted EPS | -$8.35 +80.1% |
-$41.89 -1096.9% |
-$3.50 +13.6% |
-$4.05 +6.9% |
-$4.35 -136.4% |
-$1.84 |
| Total Assets | $14.98M -41.2% |
$25.47M +111.0% |
$12.08M -44.1% |
$21.59M -42.0% |
$37.20M -36.6% |
$58.66M +378.8% |
| Cash and Equivalents | $13.20M -43.3% |
$23.29M +143.5% |
$9.56M -51.9% |
$19.87M -44.4% |
$35.70M -37.5% |
$57.17M +438.5% |
| Stockholders Equity | $8.54M -40.3% |
$14.29M +194.3% |
-$15.16M -285.9% |
$8.15M -75.3% |
$33.05M -39.7% |
$54.79M +504.8% |
| R&D Expense | $11.50M -56.0% |
$26.14M -4.1% |
$27.27M +41.9% |
$19.22M +9.3% |
$17.59M +73.4% |
$10.14M +12.7% |
| Operating Income | -$22.98M +55.6% |
-$51.78M -32.9% |
-$38.96M -35.2% |
-$28.81M -19.4% |
-$24.13M -57.8% |
-$15.29M -7.8% |
| Shares Outstanding | 4.24M +176.1% |
1.54M -92.6% |
20.74M +121.0% |
9.39M +53.6% |
6.11M -86.6% |
45.44M +384.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$4.44M | +69.7% | +18.4% |
| Diluted EPS | September 30, 2025 | -$1.41 | +88.4% | +58.4% |
| Total Assets | September 30, 2025 | $14.63M | -60.8% | +6.8% |
| Cash and Equivalents | September 30, 2025 | $12.55M | -63.4% | +13.7% |
| Stockholders Equity | September 30, 2025 | $8.00M | -47.3% | +31.4% |
| R&D Expense | September 30, 2025 | $2.52M | -54.1% | +5.6% |
| Operating Income | September 30, 2025 | -$4.85M | +63.6% | +19.7% |
| Shares Outstanding | September 30, 2025 | 3.19M | -92.1% | +76.2% |
- Cellectar Biosciences, Inc. reported Net Income of -$21.79 million for fiscal year 2025.
- Cellectar Biosciences, Inc. showed an increase of +51.1% in Net Income compared to the prior fiscal year.
- Cellectar Biosciences, Inc. reported Diluted EPS of $8.35 per share (loss) for fiscal year 2025.
- Cellectar Biosciences, Inc. showed an increase of +80.1% in Diluted EPS compared to the prior fiscal year.
- Cellectar Biosciences, Inc. reported Total Assets of $14.98 million for fiscal year 2025.
- Cellectar Biosciences, Inc. showed a decrease of -41.2% in Total Assets compared to the prior fiscal year.
- Cellectar Biosciences, Inc. reported Cash and Equivalents of $13.20 million for fiscal year 2025.
- Cellectar Biosciences, Inc. showed a decrease of -43.3% in Cash and Equivalents compared to the prior fiscal year.
- Cellectar Biosciences, Inc. reported Stockholders Equity of $8.54 million for fiscal year 2025.
- Cellectar Biosciences, Inc. showed a decrease of -40.3% in Stockholders Equity compared to the prior fiscal year.
- Cellectar Biosciences, Inc. reported R&D Expense of $11.50 million for fiscal year 2025.
- Cellectar Biosciences, Inc. showed a decrease of -56.0% in R&D Expense compared to the prior fiscal year.
- Cellectar Biosciences, Inc. reported Operating Income of -$22.98 million for fiscal year 2025.
- Cellectar Biosciences, Inc. showed an increase of +55.6% in Operating Income compared to the prior fiscal year.
- Cellectar Biosciences, Inc. reported Shares Outstanding of 4.24 million shares for fiscal year 2025.
- Cellectar Biosciences, Inc. showed an increase of +176.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: